Public policy and ethics of working with stem cells
The use of stem cells for regenerative medicine has captured the imagination of the public, with media attention contributing to rising expectations of clinical benefit. There is a clear need for ongoing public confidence in stem cell research, particularly if early applications as therapies fail or cause unforeseen problems.
Such confidence is fostered in the UK by appropriate and transparent ethical governance and regulation to match the permissive approach to embryo and stem cell research. At King’s we have a strong track record of working with regulators and government to develop the current road map toward clinical provision of cells.
Professor Fiona Watt (Director - Centre for Stem Cells and Regenerative Medicine, KCL) was an expert advisor to the House of Lords Science and Technology Select Committee.
The Committee, under the Chairmanship of Lord Krebs, launched an inquiry into regenerative medicine. The inquiry focused on UK expertise in the field, the regulatory and financial barriers to translation and commercialisation of the findings of this research, and international comparisons. The 1st Report of Session 2013-14 can be downloaded here.
- Ilina Singh (Dept of Social Science, Health and Medicine & Institute of Psychiatry)